|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loi S, Haibe-Kains B, Desmedt C, Lallemand
F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et
al: Definition of clinically distinct molecular subtypes in
estrogen receptor-positive breast carcinomas through genomic grade.
J Clin Oncol. 25:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schroeder RL, Stevens CL and Sridhar J:
Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the
treatment of aggressive breast cancer. Molecules. 19:15196–15212.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16(Suppl 1):
1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a germline
BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams S, Schmid P, Rugo HS, Winer EP,
Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al:
Pembrolizumab monotherapy for previously treated metastatic
triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086
study. Ann Oncol. 30:397–404. 2019. View Article : Google Scholar
|
|
8
|
Voorwerk L, Slagter M, Horlings HM,
Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC,
Warren S, Ong S, et al: Immune induction strategies in metastatic
triple-negative breast cancer to enhance the sensitivity to PD-1
blockade: The TONIC trial. Nat Med. 25:920–928. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ovcaricek T, Takac I and Matos E:
Multigene expression signatures in early hormone receptor positive
HER 2 negative breast cancer. Radiol Oncol. 53:285–292. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamauchi H, Nakagawa C, Yamashige S, Takei
H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chao C, et
al: Societal cost-effectiveness analysis of the 21-gene assay in
estrogen-receptor-positive, lymph-node-negative early-stage breast
cancer in Japan. BMC Health Serv Res. 14:3722014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: Discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et
al: Increases of amphiregulin and transforming growth factor-alpha
in serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa
C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, et
al: Prediction of sensitivity of advanced non-small cell lung
cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:pp.
3029–3043. 2004, View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kato T, Daigo Y, Hayama S, Ishikawa N,
Yamabuki T, Ito T, Miyamoto M, Kondo S and Nakamura Y: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph‑node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
20
|
Taniwaki M, Daigo Y, Ishikawa N, Takano A,
Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression
profiles of small‑cell lung cancers: Molecular signatures of lung
cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
21
|
Oshita H, Nishino R, Takano A, Fujitomo T,
Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, et
al: RASEF is a novel diagnostic biomarker and a therapeutic target
for lung cancer. Mol Cancer Res. 11:937–951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayama S, Daigo Y, Yamabuki T, Hirata D,
Kato T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato T, Sato N, Hayama S, Yamabuki T, Ito
T, Miyamoto M, Kondo S, Nakamura Y and Daigo Y: Activation of
Holliday junction recognizing protein involved in the chromosomal
stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki C, Takahashi K, Hayama S, Ishikawa
N, Kato T, Ito T, Tsuchiya E, Nakamura Y and Daigo Y:
Identification of Myc-associated protein with JmjC domain as a
novel therapeutic target oncogene for lung cancer. Mol Cancer Ther.
6:542–551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi K, Furukawa C, Takano A,
Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, et
al: The neuromedin U-growth hormone secretagogue receptor
1b/neurotensin receptor 1 oncogenic signaling pathway as a
therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taniwaki M, Takano A, Ishikawa N, Yasui W,
Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y:
Activation of KIF4A as a prognostic biomarker and therapeutic
target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamabuki T, Takano A, Hayama S, Ishikawa
N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, et al:
Dikkopf-1 as a novel serologic and prognostic biomarker for lung
and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Identification of a nuclear protein, LRRC42, involved
in lung carcinogenesis. Int J Oncol. 45:147–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nguyen MH, Koinuma J, Ueda K, Ito T,
Tsuchiya E, Nakamura Y and Daigo Y: Phosphorylation and activation
of cell division cycle associated 5 by mitogen-activated protein
kinase play a crucial role in human lung carcinogenesis. Cancer
Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hayama S, Daigo Y, Kato T, Ishikawa N,
Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Activation of CDCA1-KNTC2, members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirokawa N, Noda Y and Okada Y: Kinesin
and dynein super-family proteins in organelle transport and cell
division. Curr Opin Cell Biol. 10:60–73. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hill E, Clarke M and Barr FA: The
Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. EMBO
J. 19:5711–5719. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taniuchi K, Nakagawa H, Nakamura T, Eguchi
H, Ohigashi H, Ishikawa O, Katagiri T and Nakamura Y:
Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with
membrane trafficking of discs large homologue 5, can attenuate
growth of pancreatic cancer cell. Cancer Res. 65:105–112.
2005.PubMed/NCBI
|
|
35
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, et
al: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar
|
|
36
|
Saito K, Ohta S, Kawakami Y, Yoshida K and
Toda M: Functional analysis of KIF20A, a potential
immunotherapeutic target for glioma. J Neurooncol. 132:63–74. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Z, Chai C, Shen T, Li X, Ji J, Li C,
Shang Z and Niu Y: Aberrant KIF20A Expression is associated with
adverse clinical outcome and promotes tumor progression in prostate
cancer. Dis Markers. 2019:47827302019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen T, Yang L, Zhang Z, Yu J, Dai L, Gao
M, Shang Z and Niu Y: KIF20A affects the prognosis of bladder
cancer by promoting the proliferation and metastasis of bladder
cancer cells. Dis Markers. 2019:48631822019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kobayashi Y, Takano A, Miyagi Y, Tsuchiya
E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y:
Cell division cycle-associated protein 1 overexpression is
essential for the malignant potential of colorectal cancers. Int J
Oncol. 44:69–77. 2014. View Article : Google Scholar
|
|
41
|
Thang PM, Takano A, Yoshitake Y, Shinohara
M, Murakami Y and Daigo Y: Cell division cycle associated 1 as a
novel prognostic biomarker and therapeutic target for oral cancer.
Int J Oncol. 49:1385–1393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Daigo K, Takano A, Thang PM, Yoshitake Y,
Shinohara M, Tohnai I, Murakami Y, Maegawa J and Daigo Y:
Characterization of KIF11 as a novel prognostic biomarker and
therapeutic target for oral cancer. Int J Oncol. 52:155–165.
2018.
|
|
43
|
Shi C, Huang D, Lu N, Chen D, Zhang M, Yan
Y, Deng L, Lu Q, Lu H and Luo S: Aberrantly activated Gli2-KIF20A
axis is crucial for growth of hepatocellular carcinoma and predicts
poor prognosis. Oncotarget. 7:26206–26219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fontijn RD, Goud B, Echard A, Jollivet F,
van Marle J, Pannekoek H and Horrevoets AJ: The human kinesin-like
protein RB6K is under tight cell cycle control and is essential for
cytokinesis. Mol Cell Biol. 21:2944–2955. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tcherniuk S, Skoufias DA, Labriere C, Rath
O, Gueritte F, Guillou C and Kozielski F: Relocation of Aurora B
and survivin from centromeres to the central spindle impaired by a
kinesin‑specific MKLP‑2 inhibitor. Angew Chem Int Ed Engl.
49:8228–8231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Labrière C, Talapatra SK, Thoret S,
Bougeret C, Kozielski F and Guillou C: New MKLP-2 inhibitors in the
paprotrain series: Design, synthesis and biological evaluations.
Bioorg Med Chem. 24:721–734. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sakai R, Morikawa Y, Kondo C, Oka H,
Miyajima H, Kubo K and Uehara T: Combinatorial measurement of
CDKN1A/p21 and KIF20A expression for discrimination of DNA
damage-induced clastogenicity. Int J Mol Sci. 15:17256–17269. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Düzgün ŞA, Yerlikaya A, Zeren S, Bayhan Z,
Okur E and Boyacı İ: Differential effects of p38 MAP kinase
inhibitors SB203580 and SB202190 on growth and migration of human
MDA-MB-231 cancer cell line. Cytotechnology. 69:711–724. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ferrero H, Corachán A, Quiñonero A,
Bougeret C, Pouletty P, Pellicer A and Domínguez F: Inhibition of
KIF20A by BKS0349 reduces endometriotic lesions in a xenograft
mouse model. Mol Hum Reprod. 25:562–571. 2019. View Article : Google Scholar : PubMed/NCBI
|
